Developing an effective yet transparent pharmacovigilance strategy and keeping ahead of regulatory changes can be challenging, yet the EU’s complex safety regulations and ever-increasing media attention make both functions vital. At VIBpharma’s 5th annual Pharmacovigilance and Risk Management conference you will gain solutions to the issues you are currently facing; from the difficulties with RMP’s and how to effectively manage risk management with current medicines to mitigate any risks to patients.

1. VIBpharma Benef
it
to-pee from a pee
round r interacti r-
5th Annual tab ve
to add le morning
Pharmacovigilance obsta ress key
find th cles and
releva e solutio
nt to ns
and Risk Management
proce everyday
dures
Optimal PV and RM strategy and implementation to
ensure regulatory compliance and maximise drug safety
Tuesday 1 and Wednesday 2 December 2009, Brussels, Belgium
DISTINguISHED SPEAkERS INCLuDE:
Dr Thomas Verstraeten, Vice President, Head, Biologicals
Clinical Safety and Pharmacovigilance, gSk BIOLOgICALS
with 19 pharma and regulatory
representatives on the programme,
Dr Hans Joachim gamperl, Vice President, global Drug
Safety and Pharmacovigilance QPPV, FRESENIuS BIOTECH this event will provide invaluable
Craig Hartford, Executive Director, SRM/RMS Primary Care
insight into key areas of Pv and rM
Business unit Leader, PFIZER
Prof Philippe Van der Auwera, global Head of Safety Risk
Management (PDS) and Eu-QPPV, ROCHE 3 HIgHLIgHTS!
Dr Duc Vu, Director, Marketed Bilogics, Biotechnology ● Critical insights on the practical
and Natural Health Products, Marketed Health Products
Directorate, HEALTH CANADA implementation of PV on a global,
regional and country specific scale
Doris Stenver, Chief Medical Officer, Consumer Safety Division,
DANISH MEDICINES AgENCy and Pharmacovigilance Working
Party Delegate, EMEA
● Take a global approach on PV and RM
issues: clarify requirements form the
Monica Rusu, Director PharmacovigilanceEELA,
global Pharmacovigilance and Risk Management, uSA, Eastern Europe, Canada, Norway
SOLVAy PHARMACEuTICALS gMBH and Denmark to ensure compliance in
Phil Weatherill, Director, global Pharmacovigilance, IPSEN a global setting
Dr Maria grazia Zurlo, Vice President, Pharmacovigilance ● Essential case studies on ensuring
Strategy and Policy, PFIZER
legislative compliance and best practice
Erica Velthuis, Senior Pharmacovigilance Scientist and
Epidemiologist, gENZyME EuROPE
Dr Ennis Lee, Vice President and Qualified Person for Co-sponsor
Pharmacovigilance, Pharma, Benefit Risk Management,
JANSSEN CILAg
Bert Van Leeuwen, Director of global Drug Safety, ORgANON
(now part of the SCHERINg-PLOugH CORPORATION)
REgISTER NOW: ■ Email: book@vibevents.com
■ Tel: +44 (0)20 7753 4268 ■ Fax: +44 (0) 20 7915 9773
Register online now at: www.vibpharma.com/pharmacovigilance

2. Programme day one Tuesday 1 December 2009
08:30 Registration 11:40 Highlighting successful RM strategies in a post approval
setting to maximise patient safety
09:00 Opening remarks from the Chair
● Critical assessments of RM techniques and methodologies
Dr Monica Rusu, Director Pharmacovigilance EELA,
● Deciding on the best strategy for managing product risk
global Pharmacovigilance and Risk Management,
● Highlighting successful techniques to monitor RM to ensure
SOLVAy PHARMACEuTICALS
minimal risk
View from the regulators: clarifying their ● Meeting the regulators’ expectations with robust RM policies
interpretation of key PV and RM legislation ● Case study: the most effective methods for risk mitigation
Rudi Scheerlinck, Director, global Clinical Safety and
09:10 Case study: the Danish approach to PV and RM Pharmacovigilance, uCB
● Highlighting the Danish PV action plan: reviewing major
elements and objectives to ensure regulatory compliance Effective approaches to monitoring and reporting
● Clarifying the impact of significant societal trends, such as Adverse Drug Reactions (ADRs)
the internationalisation and empowerment of the citizens,
12:10 Exploiting the latest technologies and methodologies
on work practices at national level to understand how this
will affect your RM strategy
for optimal ADR monitoring and reporting
● Positioning response to adverse events at the core of your
● Establishing the interrelation between the Danish Medicines
RM activity
Agency and the EU organisation
● Developments from the cutting edge of the science and practice
● Evaluating the PSUR work share initiative and its effectiveness:
of ADR signal detection
outlining the current status from a regulatory point of view RM
● Evaluating the impact and effectiveness of electronic reporting
and risk minimisation: case study examples
Speaker TBC
Doris Stenver, Chief Medical Officer, Consumer Safety Division,
Danish Medicines Agency and Pharmacovigilance Working 12:40 Lunch and networking
Party Delegate, EMEA
Essential case studies: detailing specific
09:40 The Norwegian approach: implementing a PV plan challenges and proposing solutions
and risk minimisation activities at a national level
● Evaluating proposed RMPs: assessing how to increase their 13:50 Determining a robust drug safety strategy for vaccines
quality and usefulness to maximise the efficiency of drug to guarantee their excellence and therefore their
safety strategies acceptance for use in healthy people
● Highlighting lessons learned from the practical implementation ● Exploring the challenges to thoroughly analyse the benefit:risk
of activities proposed in RMPs to determine best practice evaluation and mitigate hazards
● Enhancing PV activities ● Generating guidelines to ensure that all adverse events are
● Reviewing educational materials to be used recorded consistently and accurately
● Handling of DHPCs ● Maximising adverse event information and data accuracy
Ingebjørg Buajordet, Head of Pharmacovigilance, through spontaneous reporting by minimising under-reporting
NORWEgIAN MEDICINES AgENCy ● Illuminating the importance of pharmacoepidemiology studies
to confirm the alerts identified by spontaneous reporting
10:10 Panel Session: Translating regulatory compliance into ● Reviewing mechanisms for active surveillance to generate
a practical, globally actionable PV strategy best practice
● Managing across multiple regulatory frameworks to ensure Dr Thomas Verstraeten, Vice President, Head, Biologicals Clinical
company-wide compliance Safety and Pharmacovigilance, gSk BIOLOgICALS
● Disseminating information and strategy effectively and creating
awareness throughout the organisation 14:20 Ensuring the safety of Orphan Drugs:
● Practical guidance on implementation through and for affiliates a company perspective
Doris Stenver, Chief Medical Officer, Consumer Safety Division, ● Tackling the internal PV challenges of a small organisation
Danish Medicines Agency and Pharmacovigilance Working ● Building a robust PV system with limited resources
Party Delegate, EMEA ● Ensuring signal detection and risk management
Ingebjørg Buajordet, Head of Pharmacovigilance, during development
NORWEgIAN MEDICINES AgENCy ● Developing signal detection and risk management
post-marketing for Orphan Drugs
10:40 Morning refreshments and networking ● The way forward…
Dr giuseppe Alvaro, Director, Drug Safety and
Achieving successful, practical implementation Pharmacovigilance, SANTHERA PHARMACEuTICALS
of PV and RM processes
11:10 Evaluating successful strategies for PV in marketed
Ensuring globally effective PV strategies
products to maximise drug safety 14:50 Highlighting the FDA’s Risk Evaluation and Mitigation
● Highlighting the key factors in PV in order to provide thorough Strategies (REMS)
information on adverse reactions and overall drug safety ● Reviewing the legislation around REMS to clarify what
● Ensuring you meet the regulators’ expectations through clear is necessary
results and increased transparency ● Determining practical insights into REMS to ensure they
● Determining best practice approaches for a successful are successful
PV strategy ● Clarifying the opportunities to integrate various global risk
● Looking towards the future: the need for increasing transparency management plans to create a global drug safety strategy
in PV and its impact on pharmaceutical companies Craig Hartford, Executive Director, SRMRMS Primary Care
Dr Ennis Lee, Vice President and Qualified Person for Business unit Leader, PFIZER
Pharmacovigilance, Pharmaceuticals, Benefit Risk
Management, JANSSEN CILAg
15:20 Afternoon refreshments and networking

3. Programme day two
15:50 Focus on Eastern Europe: reviewing the PV structure 08:30 Registration
and regulations to maximse drug safety
● Identifying the drug safety regulations in order to
09:00 Opening remarks from the Chair
Phil Weatherill, Director, global Pharmacovigilance, IPSEN
enhance compliance
● Effectively following the new legislation to maximise your
PV strategies in Eastern Europe 09:10 Roundtable morning sessions
● Reviewing methods of monitoring risk mitigation Delegates will be able to attend three one-hour roundtable
strategies efficiently discussion groups from a selection of key topics. Each ses-
● Assessing the challenges of PV in Eastern Europe to better sion will be chaired by an industry expert who will facilitate
understand where problems may occur an exchange of opinions, essential experiences and learn-
● Case study: highlighting examples of best practice to ing related to a current aspect of PV and RM
develop a comprehensive benefit:risk assessment
Dr Monica Rusu, Director Pharmacovigilance EELA, Roundtable 1
global Pharmacovigilance and Risk Management, Exploring the most effective methods for the practical
SOLVAy PHARMACEuTICALS implementation of RMPs
Risk based inspections: passing audits with This session will look at the most effective methods
flying colours for implementing your RM strategies and the different
tools you can use when gathering the data.
16:20 Preparing for risk based inspections to meet the Monica Rusu, Director PV EELA, global Pharmacovigilance
regulators’ expectations and Risk Management, SOLVAy PHARMACEuTICALS gMBH
● Reviewing the compliance report requested by the MHRA
(implemented in 2009) to fully understand what is required Roundtable 2
● Successfully deploying assessment algorithms to accurately Highlighting the role of the QPPV
interpret data
This session will explore the role QPPV and their
● Compiling an inspection readiness plan for affiliates in order
for them to address all the necessary pointers crucial role in the overall PV plan and how best to
● Facilitating interaction between the central manage risks and the scope of their role.
pharmacovigilance team and the affiliates to create a Dr Peter De Veene, Deputy European Qualified Person for
successful company wide drug safety policy Pharmacovigilance, ROCHE
Dr ute Hoeffner, European Qualified Person for
Pharmacovigilance, NOVARTIS CONSuMER HEALTH
Roundtable 3
Reviewing global compliance in PV to maximise drug
Enhancing safety monitoring processes safety at a global level
through efficient epidemiology strategies This session will explore global PV legislation and
16:50 Highlighting the importance of epidemiology in find solutions to the challenges to meet disparate
PV and RM to increase safety monitoring regulations. You will also assess how to move forward
● Evaluating the advantages of epidemiology vs to make this more viable in the future.
pharmacoepidemiology to determine how best to maximise Bert Van Leeuwen, Director of global Drug Safety,
safety monitoring ORgANON (now part of the Schering Plough Corporation)
● Exploring the need for epidemiology in clinical
development to increase the safety data available before Roundtable 4
the drug goes to market Overcoming challenges when completing PSuRs to
● Establishing the importance of epidemiology in post- ensure all safety data is up to date
marketing safety to advance the level of scientific
knowledge for a drug
This session will discuss the challenges surrounding
● Clarifying the use of epidemiology in RM to ensure safety PSURs to clarify their writing, submission and
monitoring is maximised implementation. You will also analyse the work
Erica Velthuis, Senior Pharmacovigilance Scientist and sharing initiative to assess current practices and the
Epidemiologist, gENZyME EuROPE success of the scheme.
Emphasising the role of the QPPV Dr Agnieszka Majcher-Dann, Acting Qualified Person
for Pharmacovigilance, Consumer Healthcare,
17:20 Assessing the growing importance of the QPPV in the JOHNSON & JOHNSON
evolving PV environment to understand their key role
● Clarifying the scope of the QPPV’s role to fully realise the Roundtable 5
pivotal part it plays Pharmacoepidemiology in RM: clarifying its role in
● Highlighting the challenges of the position and the legal increasing drug safety
responsibility to ensure that all requirements are met This session will look at the significant links
● Determining how the role has evolved and where it will head
between pharmacoepidemiology and clinical
in the future to assess its likely impact on PV
Dr Maria grazia Zurlo, Vice President, Pharmacovigilance development, post-marketing safety and RM to
Strategy and Policy, Pfizer highlight how it can mitigate risk.
Erica Velthuis, Senior Pharmacovigilance Scientist and
17:50 Closing remarks from the Chair Epidemiologist, gENZyME EuROPE
18:00 End of day one
12:30 Lunch

4. Wednesday 2 December 2009
Focus on new regulatory initiatives ● Developing different methods of raising awareness (types of
campaigns, leaflets and advertisements etc) to assess which
13:40 Highlighting the Developmental Safety update is most affective
Report (DSuR) to assess the implications for ● Encouraging the public to report adverse reactions through
future PV reporting increased communication to minimise under reporting
● Emphasising the implications of increasing public ● Assessing PV reporting methods used by physicians and
expectation on drug safety to determine how to encourage patients to establish clear and concise approaches
users to discuss any perceived undesirable side effect with Prof Philippe Van der Auwera, global Head of Safety Risk
their doctor or pharmacist Management (PDS) and Eu-QPPV, ROCHE
● Improving communication with health professionals,
patients and the public to increase the accuracy of post RMPs: highlighting practical advice to ensure
marketing safety data there are no gaps in your strategy
● Developing different methods of raising awareness (types
16:20 Writing an effective RMP to mitigate delays in
of campaigns, leaflets and advertisements etc) to assess
which is most affective
submission timelines
● Reviewing the key elements to be included to ensure you
● Encouraging the public to report adverse reactions through
meet the regulators’ requirements
increased communication to minimise under-reporting
● Evaluating different approaches towards risk assessment in
● Assessing PV reporting methods used by physicians and
order to include the most effective in your RMP
patients to establish clear and concise approaches
● Determining the role of epidemiological studies in risk
Bert Van Leeuwen, Director of global Drug Safety,
management to use them to their full advantage in your RMP
ORgANON (now part of the Schering Plough Corporation)
● Troubleshooting: analysing areas where pitfalls are common
14:10 Reviewing the Periodic Safety update Report (PSuR) to minimise errors and timely delays in submission
Work Sharing Initiative to evaluate its effectiveness ● Working with different departments to generate all the
● Explaining the initiative introduced to minimise duplication necessary information
● Exploring the authorities’ work processes and timeframes ● Highlighting best practice examples demonstrating effective
to be able to work to their expectations implementation techniques
● Highlighting how successful the initiative is through Dr Agnieszka Majcher-Dann, Acting Qualified Person
feedback from the authorities for Pharmacovigilance, Consumer Healthcare,
● Assessing the challenges which have arisen to evaluate JOHNSON & JOHNSON
possible solutions
16:50 Case study: best practice methods to monitor and
● Looking forward: how to make the process more efficient
Dr Marina Belle, global Pharmacovigilance, unit Manager
evaluate RM to assess the effectiveness of your RMP
● Demonstrating different methodologies to monitor RM to
PSuR, SANDOZ INTERNATIONAL
assess effective approaches
14:40 Outlining the Canadian perspective in PV activities ● Reviewing the various tools available to determine best
● Reviewing the Canadian regulatory system and Health practice in your monitoring approach
Canada activities related to the PSUR, Phamacovigilance ● Establishing appropriate methods to measure the
and Risk Management Plan (PvP/RMP) in order to meet the effectiveness of your RM strategy
requirements ● Highlighting best practice methods and lessons learned
● Highlighting the PV "tool kit" to optimise quality and efficacy Phil Weatherill, Director, global Pharmacovigilance, IPSEN
while minimising the risks that may be associated with
health products approved for sale in Canada
17:20 Experiences of a small company: submitting
● Assessing experiences and challenges encountered in the a successful RMP supporting the Eu approval of
review activities of PSUR, PvP/RMP in Canada to demonstrate a therapeutic antibody
trouble areas and best practice ● The company's drug safety and the antibody's properties as
● Establishing signal detection activities using “Canada necessary background information
Vigilance database” and other international adverse drug ● A safety strategy during clinical development as an essential
reaction databases as well as information from PSURs to tool for risk evaluation
create a global drug safety outlook ● The presentation of safety data in the dossier (CTD) impacts
Dr Duc Vu, Director, Marketed Biologics, Biotechnology the RMP
and Natural Health Products, Marketed Health Products ● The establishment of the RMP requires early planning and
Directorate, HEALTH CANADA multiple input
● Lessons learned
15:20 Afternoon refreshments Dr Hans Joachim gamperl, Vice President, global Drug Safety
and Pharmacovigilance QPPV, FRESENIuS BIOTECH gMBH
key factors in today’s changing PV environment
15:50 Increasing public awareness of risk to ensure that 17:50 Closing remarks from the Chair and champagne
patients fully understand the benefit:risk analysis prize draw
of a drug hence can take an informed decision with
their prescribing physician 18:00 End of conference
● Emphasizing the implications of increasing public
expectation on drug safety to determine how to encourage
users to discuss any perceived undesirable side effect with
their doctor or pharmacist
● Improving communication with health professionals,
patients and the public to increase the accuracy of post
marketing safety data

5. Co-sponsor About the event
Following the enormous success of our Pharmacovigilance and
Risk Management event earlier this year, VIBpharma is proud to
announce the dates for our fifth annual Pharmacovigilance and
Risk Management conference this December. The role of drug
safety both in drug development and postmarketingsurveillance
has increased enormously over recent years, especially in an
Media partners era where the public are much less tolerant to medical risk and
have many more ways in which to express their opinions. With
Pharmaceutical Technology is
a continually changing regulatory environment it is imperative
used daily as a means of creating
that you are kept up to date with the latest changes to develop a
partnerships and as a point of
robust Pharmacovigilance strategy in which there are no gaps.
reference by professionals within the pharmaceutical industry.
This comprehensive resource supplies the latest news releases,
VIBpharma’s Pharmacovigilance and Risk Management
detailed information on industry projects, white papers,
conference will bring together major pharma and biotech
event information and a thorough breakdown of products and
manufacturers as well as the regulators to find solutions to
services. www.pharmaceutical-technology.com
this increasingly important issue. This event will cover topics
Drug Development Technology is a such as effectively monitoring RMPs and best practice in
procurement and reference resource their implementation; exploring global Pharmacovigilance
providing a one-stop-shop for approaches and creating global risk minimization strategies;
professionals and decision makers within the drug development increasing public awareness of the benefit:risk ratio of
and medicines industry. We provide a comprehensive medicines and ensuring physicians fully comply to the
breakdown of drug development contractors and suppliers, Pharmacovigilance regulations; and ensuring the data exchange
up-to-date news and press releases, white papers and detailed between companies.
information on current industry projects and trends. Our
recruitment area provides career information and the latest job This educational two-day conference, tailored to maximise the
vacancies in the field. www.drugdevelopment-technology.com sharing of knowledge and expertise and to promote networking
for professionals in this area, will ensure you effectively
The Business Review websites are manage Risk Management with current medicines to mitigate
your number one stop for all the any risks to patients.
latest news, comment and industry information. Each Business
Review website offers content that is produced by a dedicated
team of journalists and global industry experts. In addition to
the free content made available on the sites an intelligence store TESTIMONIALS – Here is what previous delegates
will provide you with premium market analysis reports from the have said about previous PV conferences
leading global suppliers of market research and industry analysis.
“Very useful with a lot of hot topics”
Pharmaceutical Business Review is Patient Safety Manager, ASTRAZENECA
the world's leading pharma website,
being used by over 100,000 visitors “Very good to meet people; fruitful discussions”
every month. For further information CQA PV Specialist, NOVARTIS
contact jsharp@industryreview.com “It was very useful and lively meeting and I have the
opportunity to interact with many other colleagues
World Pharmaceutical Frontiers not only from the pharma industry but also the
The pharmaceutical industry is
World Pharmaceutical Frontiers www.worldpharmaceuticals.net
regulators. We shared a lot of experience and I
changing fast. There are more regulations, technologies,
learned a lot!”
faster product launches and shorter product life cycles than
Director of PV, SOLVAy PHARMA
ever before. World Pharmaceuticals frontiers is, and will
continue to be, at the forefront of these changes, so visit us “A good choice of speakers and enough time devoted
at www.worldpharmaceuticals.net and stay up to date with all to discussion”
latest developments Head of Drug Safety, BOEHRINgER INgELHEIM
“Globally a good overview with current practices
and issues in PV. A good opportunity to exchange
Who should attend: experiences with colleagues”
Heads, Directors and Managers from pharma and biotech Senior Director, Safety and Compliance, IPSEN
manufacturers working in the following areas: INNOVATIONS
● Pharmacovigilance ● Clinical Operations “Good interaction and variety of speakers. Overall I
● Qualified Person ● Clinical Safety enjoyed the experience and exchanged best practice
(QP) for PV ● Epidemiology with others”
● Drug Safety ● Product Safety and PV Manager, SCHERINg PLOugH
● Benefit-Risk Management Quality Management “Very high quality speakers and the roundtable
● Medical ● Regulatory Affairs discussion groups allowed a good exchange of
● Risk Management experiences”
Drug Safety Specialist, MERCk SERONO
“Very good, well organised conference”
Do you wish to exhibit your products Director, Marketed Biologicals, HEALTH CANADA
and services at this exclusive event? “Highly professional speakers and audience, very
knowledgeable and open. Pleasant overall”
Contact details: Paul Adams, Drug Safety Solution Manager, QuINTILES
pauladams@arena-international.com, +44 (0) 20 7753 4259

6. Booking Form
Pharmacovigilance and Risk Management, Tuesday 1 and Wednesday 2 December 2009, Brussels, Belgium
Yes, i would like to register for the event: Before Before After ■ Register online at
6.10.2009 3.11.2009 3.11.2009
www.vibpharma.com/pharmacovigilance
i am a Pharma Manufacturer/biotech representative and i would like to register for the event:
I would like to attend the 2-day conference + the interactive €2590 €2730 €2940 ■ Email us at
CD-ROM (saving €70) † events@arena-international.com
I would like to attend the two day conference only €1960 + VAT @ €2100 + VAT @ €2310 + VAT @ ■ Tel +44 (0)20 7753 4268
21% = €2371.60 21% = €2541 21% = €2795.10
■ Fax +44 (0)20 7915 9773
i am an Academic representative and i would like to register for the event:
I would like to attend the 2-day conference + the interactive €1680 €1820 €2030 Venue Details
CD-ROM (saving €70) † The two day conference will take place on Tuesday
€1050 + VAT @ €1190 + VAT @ €1400 + VAT @ 1 and Wednesday 2 Dec 2009, in Brussels, Belgium
I would like to attend the two day conference only 21% = €1270.50 21% = €1439.90 21% = €1694
at the Sheraton Brussels Airport Hotel For further
fees for all other attendees information contact our Operations department on
+44 (o) 207 753 4201.
I would like the VIP Package attendees package to €3590 €3730 €3940
include the two day conference + interactive CD-ROM
Are you registered?
I would like to attend the two day conference €2960 + VAT @ €3100 + VAT @ €3310 + VAT @ You will always receive an acknowledgement of your
21% = €3581.60 21% = €3751 21% = €4005.10
booking. If you do not receive anything, please call
I cannot attend the conference but would like to receive €700 €700 €900 us on +44 (0) 20 7753 4268 to make sure we have
the interactive CD-ROM † received your booking.
† VAT where applicable
Discount code if applicable _________________________
Total Discounts are at the discretion of Arena International and are not cumulative All total fees are subject to a 2.5% service charge
Arena International Conference Delegate terms and conditions 5 General: You, your executive/s or your agents may not transfer or assign any of the rights or obligations of this
1. Scope of Agreement: These are the conditions of the contract between you, the Client (“You” and “your”) and Arena Agreement (in whole or part) without our prior consent. Any attempt to resell, assign or transfer rights without our consent
International Events Group (“Arena International Events Group”, “we”, “us” and “our”) governing your use of our will entitle us to cancel the contract without liability to you.
services, including the conference registration as set out in your booking form. This agreement constitutes the entire • This agreement is governed by and will be construed in accordance with English law and each party irrevocably
agreement between Arena International Events Group and you. All prior agreements understandings and negotiations and agrees that the courts of England will have the non-exclusive jurisdiction to deal with any disputes arising out of or in
representations (save for fraudulent misrepresentation) whether oral or in writing are cancelled in their entirety. The terms of connection with this agreement.
any other electronic communications will not form part of this agreement. • Grant of Licence: If your booking includes the CD-ROM, you warrant that you will only use the CD-ROM for your business
2 Our commitment to you: Should the Event be cancelled or the location be changed for reasons or circumstances beyond purposes and shall not, without our prior written consent, make available, copy, reproduce, transmit, disseminate, sell, licence,
our control, we reserve the right to reschedule the Event, including changing the location, upon written notice to you. Should distribute, publish, broadcast or otherwise circulate the CD-ROM (or any part of it) to any other person other than in accordance
the event fail to be rescheduled for any reason your refund shall not exceed the total charge received by us from you. with these terms and conditions.
3 Payment Terms: The Total Fees specified on the booking form are subject to an additional service charge of 2.5% • Arena International Events Group is subject to the UK Data Protection Act 1998 and is registered in the UK with the
(“Service Charge”) applied to cover administration costs, and are exclusive of VAT and any other applicable sales tax Information Commissioner to process your personal information. Our primary goal in collecting personal information from
which shall be payable in addition. you is to give you an enjoyable customised experience whilst allowing us to provide services and features that most
• Following completion and return of the booking form, full payment including Service Charge is required within five days likely meet your needs. We collect certain personal information from you, which you give to us when using our Sites
from the invoice date or prior to the event if this is sooner. All registrants must provide a credit card number as a guarantee and/or registering or subscribing for our products and services. We also collect certain personal data from other group
at the time of booking. We reserve the right to charge your card in full if payment is not received in accordance with these companies to whom you have given information through their websites. If you do not want us to continue using this
payment terms. We reserve the right to refuse admission if full payment is not received in accordance with these terms. information please notify us at unsubscribe@arena-international.com. Any personal information supplied to SPG Media
4 Cancellations: In the event of cancellation, 100% of the event fee is payable and non-refundable. All cancellation requests Ltd as part of this registration process and/or any other interaction with SPG Media Ltd will be collected, stored and used
must be submitted to us in writing by Monday 2 November 2009. If we agree to your cancellation then all cancellation fees are by SPG Media Ltd its subsidiaries, related companies or affiliates in accordance with the SPG Media Ltd Privacy Policy.
payable immediately after the acceptance of your cancellation in writing by us. Please email privacypolicy@arena-international.com for a copy of the SPG Media Ltd Privacy Policy.
• If you are a Biotech/Pharma Manufacturer and have signed up as a free of charge delegate, you will incur a charge of $499 • The working language of the Event is English. Executives requiring an interpretation service must make their own
if you cancel your registration. arrangements at their own expense.
Arena International Events Group, a trading division of SPG Media Ltd. Registered Office: 55 North Wharf Road, London, W2 1LA, UK. Registered in England No. 01155599. www.arena-international.com
Delegate Details please photocopy form for multiple bookings
Mr/Mrs/Ms/Dr First Name: Surname:
Email: Tel:
Job Title: Fax:
Department:
Company Details
Company: Address:
Town:
Postcode: Country:
VAT Number: Nature of Business:
Payment Details
Purchase Order No.
■ I enclose a cheque drawn on a UK bank (please make cheque payable to SPGMedia Limited and write reference PCVR1209 on the reverse)
■ I will transfer payment to your Lloyds TSB account City Branch, London, UK: 01492549, sort code 30-00-02 (using reference PCVR1209)
■ I would like to pay with my credit card ■ Visa ■ Mastercard ■ AMEX ■ Maestro ■ Solo
Card Number: Expiry Date: Issue Date: CSV*:
Cardholder's Name:
Cardholder's Address:
*The CSV number is the last 3 digit number on the reverse of the card
■ Yes, I have read and understood the terms and cancellations conditions and am happy to proceed with my registration MKEH
Signature Date